History of Taj Pharma Group

Vision Born of Innovation | Legacy Built on Science

The history of Taj Pharma Group is a testament to visionary leadership, deep pharmaceutical acumen, and relentless pursuit of quality. Founded by Dr. R. K. Singh, a pioneering entrepreneur and a strong proponent of the generic pharmaceutical revolution, Taj Pharma has grown into a global pharmaceutical powerhouse recognized for its innovation, compliance, and global presence.


1995 – The Genesis: Enterprise Incorporation

In 1995, Dr. R. K. Singh laid the foundation of a modest pharmaceutical trading enterprise with a focus on making affordable generic medicines accessible to Indian hospitals and patients. His belief that the future of healthcare lies in standardized, quality-controlled generics led to the early adoption of WHO guidelines and product documentation systems.


2004 – Incorporation of Taj Pharmaceuticals Ltd. as a Public Company

With the increasing scale of operations and an expanding portfolio of Active Pharmaceutical Ingredients (APIs), finished formulations, and specialty medicines, the enterprise was formally incorporated as Taj Pharmaceuticals Ltd. This step marked the beginning of structured R&D investments and in-house dossier development for regulated and semi-regulated markets.

Taj Pharma also began establishing international affiliate operations in Mauritius, Malaysia, Dubai, Russia, France, and the UK, expanding the company’s global reach.


2007 – Indian Domestic Market Entry

The year 2007 marked the launch of Taj Pharma’s branded generics portfolio in the Indian market, with a focus on chronic therapies including cardiology, psychiatry, oncology, gastroenterology, and antiretrovirals (ARVs). The company adopted a pan-India model through C&F agents, stockists, and 1,200+ medical representatives across all zones.


2008 – Entry into International Export Markets

Taj Pharma entered the Middle East and North Africa (MENA) region, with strategic exports of finished formulations to Lebanon, Iraq, and the Gulf Cooperation Council (GCC) countries. Product registration efforts were supported by ICH CTD-format dossiers, and Taj Pharma achieved its first MOH (Ministry of Health) approvals abroad.

This expansion laid the foundation for the company’s global export strategy, which now includes regulatory submissions in over 42 countries.


2011 – Formation of TAJ PHARMA INDIA LIMITED: OSD Plant, Sarigam

Taj Pharma commissioned a State-of-the-art Oral Solid Dosage (OSD) facility in Sarigam GIDC, Vapi-Daman Industrial Zone, Gujarat, India. This WHO-GMP certified plant was designed with:

  • 3 production blocks for Tablets, Capsules, and Oral Powder, Dry Syrups
  • Dedicated BMR/BPR, IPQC labs, and HVAC systems
  • Fully segregated processing areas with unidirectional flow
  • Output: 500 million tablets/month, scalable to 1 billion/month

This plant became the heart of Taj Pharma’s regulated market dossier support for antimalarials, antibiotics, anti-TB, anti-HIV, and CNS drugs.


2014 – Corporate Expansion in Ahmedabad

Taj Pharma opened its Corporate Marketing and Commercial Headquarters in Ahmedabad, Gujarat. This office serves as the nerve center for:

  • Global dossier filings (EU CTD, US eCTD, ACTD, CAF)
  • International tender management (Global Fund, UNDP, MOH Procurement)
  • Strategic partnerships and B2B licensing deals

2014–2018 – Rapid Scale through Loan Licensing and FDA Approvals

Between 2014 and 2018, Taj Pharma dramatically expanded its manufacturing footprint through over 40 loan license (contract manufacturing) tie-ups across India, primarily for high-volume hospital lines, injectables, and beta-lactams.

By 2018, Taj had secured FDA permissions for over 4,600 molecules under the Indian DCGI framework — one of the highest in the country — including approvals for niche therapies such as:

  • Oncology injectables
  • Bi-layer tablets
  • Fixed-Dose Combinations (FDCs) under WHO Prequalification formats

2019 – COVID-19 Pandemic Response

During the COVID-19 outbreak, Taj Pharma was among the top 10 companies in India to develop and manufacture essential antivirals:

  • Remdesivir for hospitalized patients
  • Favilavir (Favipiravir) for mild to moderate COVID cases
  • Molnupiravir under emergency use authorizations

The company ensured GMP-compliant supply through fast-tracked stability studies, validation batches, and expedited regulatory filings, contributing to national and international relief efforts.


2021 – Viramgam Manufacturing Project: A 15-Acre Block-Based Pharma Complex

Taj Pharma initiated the construction of a 15-acre greenfield pharmaceutical manufacturing complex in Viramgam, Gujarat. This project includes:

  • Multiple manufacturing blocks for oncology, injectables, and biosimilars
  • High-volume cephalosporin & penem injectable lines
  • Dedicated R&D Pilot Plant and QC Microbiology Lab
  • Fully compliant with PICS and EU GMP guidelines

Phase 1 is expected to handle oncology vials and lyophilized injections with EU submissions targeted in 2026.


2022 – Sarigam Plant Upgrade to EU GMP Compliance

The Sarigam OSD plant underwent full conversion to meet EU-GMP standards, including:

  • Modular cleanroom panels
  • HEPA filtration upgrades
  • Electronic BMR/BPR systems integration
  • Regulatory support through QP audits, EU GMP gap assessments, and submission to EU authorities

The upgrade enables Taj Pharma to serve regulated markets in Europe and Latin America directly from India.


2025 – Kalgam SVP Injectable Plant: Commissioning in Progress

Taj Pharma has commenced the construction and commissioning of its new SVP (Small Volume Parenteral) Injectable facility in Kalgam Industrial Zone, Gujarat. The plant features:

  • High-speed ampoule and vial filling lines
  • WFI generation system with double RO + EDI + distillation
  • Grade B aseptic manufacturing suites
  • Fully automated autoclaves, terminal sterilizers, and depyrogenation tunnels

This plant will support production of anaesthesia products, sterile antibiotics, vaccines, and critical care injectables for both domestic and international tender markets.


Legacy & Future Vision

Today, Taj Pharma is positioned as a technology-driven, quality-focused pharmaceutical group, operating with the belief that “Medicine is for Life.”

With a growing pipeline of biosimilars, NDDS (Novel Drug Delivery Systems), and oncology drugs, and continuous investments in compliance, capacity, and R&D, the company aims to expand its reach in EU, US, LATAM, CIS, and Africa.

The Taj legacy, under the guidance of Dr. R. K. Singh, continues to evolve — delivering innovation, affordability, and accessibility for global healthcare.


Global Certifications & Compliance

  • WHO-GMP, PICS, EU-GMP (in progress)
  • ISO 9001:2015, ISO 13485
  • MOH Approvals: Kenya, Iraq, UAE, Ghana, Cambodia, Philippines
  • CTD/eCTD Dossiers Available for 2,800+ molecules